Global Acquired Hemophilia Treatment Market Trends and Future Outlook to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Acquired Hemophilia Treatment Market?
The market for treating acquired hemophilia has seen robust growth in the past few years. There’s an expected increase from $12.2 billion in 2024 to $12.83 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. The growth witnessed in the previous years is a result of diverse contributing factors such as the growing elderly population, enhanced diagnostics and awareness, an enlarging base of patients, joint research initiatives, and regulatory backing and approvals.
In the upcoming years, the market size for the treatment of acquired hemophilia is predicted to experience consistent growth, reaching to $15.24 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 4.4%. The expansion during this forecast period can be attributed to factors such as the increasing global population, amplified investment in healthcare, the advent of personalized medicine, international research partnerships, heightening healthcare awareness and regulatory backing for orphan drugs. Key trends anticipated in this timeframe include, the advancement of monitoring and diagnostic technologies, partnerships for patient support programs, exploration into gene therapy approaches, an upswing in the utilization of immune tolerance induction, and the use of telemedicine for remote consultations.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13363&type=smp
What Drivers Are Accelerating Expansion Of The Acquired Hemophilia Treatment Market?
The acquired hemophilia treatment market is set to surge due to an increasing number of continuous clinical trials. These trials, conducted on human subjects, test the safety and effectiveness of novel medical procedures, treatments, or diagnoses. In particular, these research studies focus on assessing the safety and efficacy of new treatments for acquired hemophilia, propelling research to boost patient results and confirm successful therapeutic interventions. As mentioned in ClinicalTrials.gov, a division of the National Institutes of Health (NIH), the agency on the frontlines of conducting and promoting medical research in the U.S., the number of registered investigations jumped from 437,523 in 2022 to 468,457 in all 50 states in America and 221 countries worldwide in October 2023. Furthermore, out of this, 143,613 studies (representing 31% of the total) are registered solely in the U.S. while 251,159 studies (making up 54% of the total) are registered in locations outside the U.S. Hence, this escalation in ongoing clinical trials is powering the expansion of the acquired hemophilia treatment market.
What Are The Key Segment Trends Observed In The Acquired Hemophilia Treatment Market?
The acquired hemophilia treatmentmarket covered in this report is segmented –
1) By Treatment: On-Demand; Prophylaxis
2) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
3) By End User: Hospitals; Clinic; Other End Users
Subsegments:
1) By On-Demand: Clotting Factor Replacement Therapy; Desmopressin; Other On-Demand Treatments
2) By Prophylaxis: Clotting Factor Replacement Therapy; Gene Therapy; Other Prophylaxis Treatments
Which Long-Term Trends Will Play A Crucial Role In The Acquired Hemophilia Treatment Market?
Leading firms in the acquired hemophilia treatment market are concentrating on bringing out medications with added safeguards and earning regulatory approval to stay competitive. Approvals for drugs incorporating routine prophylaxis measures are on the rise, driven largely by the demand for more efficient, safer solutions. For example, in June 2022, Japan’s Chugai Pharmaceutical was granted an expanded approval from the country’s Ministry of Health, Labor and Welfare for its Hemlibra (emicizumab) therapy. This allows the prophylaxis drug to help prevent or lessen the incidence of bleeding in patients suffering from acquired hemophilia A. After this endorsement was given, further actions to swiftly manage and restrict bleeding following a diagnosis using Hemlibra were permitted. Hemlibra is a bispecific antibody that concurrently binds to two crucial targets, factor IX and factor X, at their respective binding sites during the blood coagulation process.
Who Are The Major Stakeholders Operating In The Acquired Hemophilia Treatment Market?
Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report
What Regional Factors Are Accelerating Growth In The Acquired Hemophilia Treatment Market?
North America was the largest region in the acquired hemophilia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13363&type=smp
Browse Through More Reports Similar to the Global Acquired Hemophilia Treatment Market 2025, By The Business Research Company
Hemophilia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report
Compressed Air Treatment Equipment Global Market Report 2025
Chemical Seed Treatment For Ornamental And Turf Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
